Caroline Seymour

Treatment with pemigatinib resulted in a durable objective response rate in 35.5% of patients with previously treated, locally advanced or metastatic cholangiocarcinoma who harbored an FGFR2 fusion or rearrangement.

Jasmine M. Zain, MD, discusses the phase III ECHELON-2 trial and the ongoing work being done in peripheral T-cell lymphoma and other T-cell lymphomas.

Carey K. Anders, MD, discussed current approaches in the management of patients with breast cancer that has metastasized to the brain.

Miguel A. Villalona-Calero, MD, discusses the availability of ALK inhibitors for patients with ALK-positive non–small cell lung cancer and the importance of implementing sequencing panels to guide treatment.

Nivolumab monotherapy demonstrated promising activity in a small number of patients with recurrent or metastatic cervical, vaginal, and vulvar cancer.

John M. Timmerman, MD, discusses the research being conducted across the spectrum of Hodgkin and non-Hodgkin lymphoma.

Matthew G. Mei, MD, discusses current considerations in the frontline management of advanced-stage Hodgkin lymphoma as well as ongoing investigations with checkpoint inhibitors and cellular-based therapy.

Andrew D. Zelenetz, MD, PhD, discusses the use of emerging targeted therapies in mantle cell lymphoma.

Sarah M. Larson, MD, discusses trials with the potential to shift treatment strategies in the frontline and relapsed/refractory settings of multiple myeloma and remaining research questions in the field.

Serial assessment of blood-based immune markers showed that the risk of progression from monoclonal gammopathy of undetermined significance, the precursor disease to multiple myeloma is fluctuating rather than determinate, and these patients can experience progression to myeloma within 5 years.

Herbert A. Eradat, MD, explains how insight into the pathogenesis of chronic lymphocytic leukemia is leading to novel treatment strategies and shed light on unmet needs in the field.

Christopher S. Seet, MD, PhD, discusses elements of treatment discontinuation in chronic myeloid leukemia.

Patients with metastatic colorectal cancer who harbored BRAF non-V600, RAS-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF non-V600, RAS-independent mutations.

Shubhada Dhage, MD, FACS, discusses the role of surgery and other therapeutic modalities in breast cancer and explained the shift toward de-escalated treatments and less morbid surgical management strategies.

Naomi Fujioka, MD, discusses the clinical implications of the PACIFIC trial in NSCLC treatment and additional questions that are informing planned and ongoing trial designs in stage III disease.

Gary H. Lyman, MD, MPH, discusses the current parameters used to develop a biosimilar, the impact these products have had in the treatment and supportive care settings, and ongoing initiatives to address remaining challenges.

Joshua P. Sasine, MD, PhD, spotlights some of the strategies under investigation to improve the safety and efficacy of CAR T-cell therapy in hematologic malignancies.

Tanya Siddiqi, MD, discusses the novel agents that have emerged in the treatment paradigm for patients with chronic lymphocytic leukemia.

Nina D’Abreo, MD, explains how treatment is being tailored to women with early-stage, HR-positive, HER2-negative breast cancer.

Two distinct subtypes of nonfunctional pancreatic neuroendocrine tumors could help prognosticate risk of recurrence following surgery.

Lee S. Schwartzberg, MD, discusses the mission of OneOncology as well as the work that is being done to bring biosimilars to the market.

Rebecca C. Arend, MD, discusses several ongoing trials exploring the use of immunotherapy in patients with advanced ovarian cancer.

Debra Richardson, MD, FACOG, FACS, discusses the current indications for PARP inhibitors in the recurrent setting and ongoing work being done to broaden their utility in the field.

Parminder Singh, MD, discusses ongoing research in advanced urothelial cancer and the focus on incorporating precision medicine in the field.

Manish Kohli, MD, discusses the agents that have redefined the treatment paradigm of metastatic prostate cancer and details ongoing work to elucidate genomic classifiers.

Alexander Olawaiye, MD, discusses the trials that led to the expanded approvals of PARP inhibitors as maintenance therapy in women with platinum-sensitive ovarian cancer.

Jessica L. Berger, MD, evaluates the treatment approaches available for patients with newly diagnosed advanced ovarian cancer.

Madeleine B. Courtney Brooks, MD, MPH, sheds light on the current treatment paradigm of recurrent ovarian cancer.

David D. Thiel, MD, provides perspective on the CARMENA findings in metastatic renal cell carcinoma.

Hans-Christian Kolberg, MD, discusses the design of the LILAC study, the cardiac safety profiles of ABP 980 and reference trastuzumab, and patient and provider comfort with ABP 980 in practice.